secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akero Therapeutics, Inc. (—)
CIK:        0001744659
Form:       8-K
Filed at:   2025-12-09T23:59:59+00:00
Accession:  0001140361-25-044946
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akero Therapeutics acquired by Novo Nordisk at $54/share plus potential $6 CVR
------------------------------------------------------------------------------

- Merger closed Dec 9, 2025; each share converted to $54 cash plus one CVR worth up to $6.
- Company common stock delisted from Nasdaq; trading suspended Dec 10, 2025.
- All prior directors and executive officers resigned; new directors appointed from Merger Sub.
- Certificate of incorporation and bylaws amended and restated post-merger.
- Company becomes wholly owned subsidiary of Novo Nordisk.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1744659/000114036125044946/0001140361-25-044946-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1744659/000114036125044946/ef20060786_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-044946

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer